Encapsulating peritoneal sclerosis (EPS) is an intestinal obstruction syndrome in which peritoneal deterioration and intraperitoneal inflammation result in intestinal adhesions, which are covered with a fibrin capsule and cause bowel obstruction. The widespread use of peritoneal dialysis (PD) has been associated with an increase in the number of patients with this life-threatening complication. For this reason, some negative comments have been made about PD therapy. However, recent clinical studies have elucidated the pathogenesis of EPS and proposed therapeutic strategies.
Currently, these facts are known:
EPS occurs in 2.5% of all patients (3.18/1000 patient-years).
A longer duration of PD is associated with a higher incidence of EPS and a poorer prognosis, indicating the involvement of peritoneal deterioration in the development of EPS.
Development of EPS involves some kind of infection.
Development of EPS frequently occurs after PD withdrawal and catheter removal.
Peritoneal lavage after PD withdrawal delays, but cannot prevent the development of EPS.
Timely administration of steroids is effective.
Surgical adhesiolysis is the optimal treatment to relieve bowel obstructions, but does not exclude the potential for re-adhesions, requiring various ingenious gastrointestinal surgical techniques.
NomotoYKawaguchiYKuboHHiranoHSakaiSKurokawaK.Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis1996; 28:420–7.
2.
RigbyRJHawleyCM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant1998; 13:154–9.
3.
KawaguchiYSaitoAKawanishiHNakayamaMMiyazakiMNakamotoH. Recommendations on the management of encapsulating peritoneal sclerosis in Japan, 2005: diagnosis, predictive markers, treatment, and preventive measures. Perit Dial Int2005; 25(Suppl 4):S83–95.
4.
KawanishiHKawaguchiY.Prevalence and therapeutic outcome of sclerosing encapsulating peritonitis (EPS)—a multicenter study in Japan (Japanese). Jin To Toseki2000; 49(Suppl):225–8.
KawanishiHKawaguchiYFukuiHHaraSImadaAKuboH. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis2004; 44:729–37.
7.
DobbieJW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int1992; 12:14–27.
8.
De VrieseASTiltonRGStephanCCLameireNH. Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol2001; 12:1734–41.
9.
KawanishiHHaradaYNoriyuki T KawaiTTakahashiSMoriishiM. Treatment options for encapsulating peritoneal sclerosis based on progressive stage. Adv Perit Dial2001; 17:200–4.
10.
KawanishiHFujimoriATsuchidaKTakamotoYTomoTMinakuchiJ. Markers in peritoneal effluent for withdrawal from peritoneal dialysis: multicenter prospective study in Japan. Adv Perit Dial2005; 21:21–4.
11.
YamamotoRNakayamaMHasegawaTNumataMYamamotoHYokoyamaK. High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial2002; 18:131–4.
12.
WilliamsJDTopleyNCraigKJMackenzieRKPischetsriederMLageC. on behalf of the Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (Balance) on the peritoneal membrane. Kidney Int2004; 66:408–18.
13.
PirainoBBailieGRBernardiniJBoeschotenEGuptaAHolmesC. on behalf of the ISPD Ad Hoc Advisory Committee. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int2005; 25:107–31.
14.
NakayamaMYamamotoHIkedaMHasegawaTKatoNTakahashiH. Risk factors and preventive measures for encapsulating peritoneal sclerosis—Jikei experience 2002. Adv Perit Dial2002; 18:144–8.
15.
MoriishiMKawanishiHKawaiTTakahashiSHiraiTShishidaM. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis. Adv Perit Dial2002; 18:149–53.
16.
AllariaPMGiangrandeAGandiniEPisoniIB. Continuous ambulatory peritoneal dialysis and sclerosing encapsulating peritonitis: tamoxifen as a new therapeutic agent?J Nephrol1999; 12:395–7.
17.
EltoumMAWrightSAtchleyJMasonJC. Four consecutive cases of peritoneal dialysis–related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int2006; 26:203–6.
18.
del PesoGBajoMAGilFAguileraARosSCosteroO. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial2003; 19:32–5.
19.
JunorBJMcMillanMA. Immunosuppression in sclerosing peritonitis. Adv Perit Dial1993; 9:187–9.
20.
MoriYTatsuoSSutohHToriyamaTKawaharaHHottaN.A case of a dialysis patients with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis1997; 30:275–8.
21.
KawanishiHHaradaYSakikuboEMoriishiMNagaiTTsuchiyaS.Surgical treatment for sclerosing encapsulating peritonitis. Adv Perit Dial2000; 16:252–6.
22.
KawanishiHMoriishiMTsuchiyaS.Experience of 100 surgical cases of encapsulating peritoneal sclerosis: investigation of recurrent cases after surgery. Adv Perit Dial2006; 22:60–4.
23.
NobleTB. Plication of small intestine as prophylaxis against adhesions. Am J Surg1937; 35:41–4.
24.
SeabrookDBWilsonND. Prevention and treatment of intestinal obstruction by use of the Noble procedure. Am J Surg1954; 88:186–93
